The latest from BioStock
» Biosergen to dose first patient with life-threatening fungal disease
» PHI aims for US listing
» Alzinova doses all patients in the high-dose portion
» Cereno's CEO comments on advancement with CS1 and CS014
» Danish leads among life science stocks in the first half of the year
The latest news of the day
receives its second Fast Track Designation for Diamyd by the FDA for the prevention of type 1 diabetes. Read more.
Sobi announces the publication of complete results from the Phase III XTEND-Kids study in The New England Journal of Medicine. Read more.
Bavarian Nordic receives EMA application, approval and validation of market approval for its Chikungunya vaccine. Read more.
By having receives Notice of Allowance from the US Patent Office. Read more.
The board of directors Enzymatica decides on a new share issue of approximately SEK 130 million. Read more. The company updates the financial targets and calls an extraordinary general meeting. Read more here and here.
ContextVision is expanding its product pipeline to include data quality. Read more.
BioPorto announces that preliminary data suggest potential uses for NGAL biomarkers beyond early AKI diagnosis. Read more.
SoftOx Solutions proposes a new share issue of 22,5 MNOK and calls an extraordinary general meeting. Read more.
Medivir presents updated clinical data for fostrox + Lenvima in liver cancer at ISMO in September. Read more.
Implantica launches advanced training programs for RefluxStop in Spain. Read more.
Initiator Pharmas International patent application regarding dosage of pudafensine for the treatment of erectile dysfunction has been published. Read more.
C-ROW has decided to repurchase its own shares. Read more.
Qlife holds a record date for the reverse stock split on July 31. Read more.
ProstaLund announces the last day for trading in BTU and the first day for trading in warrants of series TO 3. Read more.
AlzeCure Pharma carries out a directed new share issue in follow-up to a previously submitted subscription commitment. Read more.
PolarCool enters third contract period with German ice hockey club Adler Mannheim. Read more.
Realheart carries out a directed new issue of units to guarantors in connection with the rights issue. Read more.
The results from Cancerous FRACTAL study to be presented at ESC 2024. Read more.
Biotage informs about the conversion of C shares into common shares and the transfer of common shares within the framework of the long-term performance-based incentive program. Read more.
Perpetua Medical appoints Mangold Fondkommission as liquidity guarantor. Read more.
Staffan Torstensson appointed as new CEO of ADDvise, CFO and incoming CEO is leaving. Read moreThe company calls an extraordinary general meeting. Read more.
Reports
Annex C-Row Dynavox Group Genmab Getinge Hansa Biopharma Magle Group Orthoma Stille ViroGates
Communiqués
Arcede Pharma Genetic Analysis Observe Medical
This morning's price development
Index: OMXS30 +0,52% Healthcare +0,93%
| Winner | Förlorare |
| Ecti Research +63,2% | ADDvise Group -15,7% |
| Odinwell 22,8% | Enzymatica -15,3% |
| Getinge +11,1% | Alteco -14,8% |
| Diamyd Medical +10,5% | Hansa Biopharma -14,0% |
| Monivent 10,1% | SoftOx Solutions -12,8% |